Induction of circulating IL-1 receptor antagonist by IFN treatment
The DOI matches its Crossref record.
Abstract
This study was undertaken to determine whether IFN induce IL-1 receptor antagonist (IL-1Ra), a specific inhibitor of IL-1. Plasma samples were obtained from healthy volunteers (n = 5) and patients with chronic hepatitis C (n = 5) treated with IFN-alpha, and from patients with renal cell carcinoma (n = 6) treated with IFN-gamma and assayed for IL-1Ra by a specific radioimmunoassay. Both types of IFN were administered subcutaneously. In vitro studies were carried out with PBMC from healthy volunteers. A single, low and nontoxic dose (1 x 10(6) U) of IFN-alpha induced circulating IL-1Ra, which reached peak levels within 12 h. This effect was dose-dependent and more pronounced with a higher dose (5 x 10(6) U). Peak IL-1Ra levels 12 h after 5 x 10(6) U IFN-alpha were 4.16 +/- 0.35 ng/ml in healthy volunteers and 5.7 +/- 0.73 ng/ml in patients with chronic hepatitis C (difference not significant). Thereafter levels declined but remained elevated for 24 h. IFN-gamma treatment led only to a modest increase of circulating IL-1Ra even at a dose of 400 micrograms; this dose, however, was associated with side effects similar to those seen after injection of 5 x 10(6) U IFN-alpha. PBMC stimulated with IFN-alpha or IFN-gamma produced IL-1Ra in vitro. The induction of IL-1Ra may contribute to the antiviral, anti-inflammatory, and antiproliferative effects of IFN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor
Agnello, V., Ábel, G., Elfahal, M., Knight, G. B., & Zhang, Q.-X. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12766 · Cited by 974
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
Self-citationCytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Role of interferons and other cytokines in the regulation of the immune response
Belardelli, F. (1995) · APMIS · doi:10.1111/j.1699-0463.1995.tb01092.x · Cited by 471
Mayer-Barber, K. D., Andrade, B. B., Barber, D. L., Hieny, S., Feng, C. G., Caspar, P., Oland, S., Gordon, S., & Sher, A. (2011) · Immunity · doi:10.1016/j.immuni.2011.12.002 · Cited by 418
Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury
Toldo, S., Mauro, A. G., Cutter, Z., & Abbate, A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00158.2018 · Cited by 369
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Self-citationAnti-inflammatory properties of pro-inflammatory interferon-γ
Mühl, H., & Pfeilschifter, J. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(03)00131-0 · Cited by 277
Cytokine induction by the immunomodulators imiquimod and S-27609
Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L., & Tomai, M. A. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.58.3.365 · Cited by 265
Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., & Neveu, P. J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00030-0 · Cited by 201
Treatment of cytokine-induced depression
Capuron, L., Hauser, P., Hinze-Selch, D., Miller, A. H., & Neveu, P. J. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00007-7 · Cited by 132
Terui, T., Hirao, T., Sato, Y., Uesugi, T., Honda, M., Iguchi, M., Matsumura, N., Kudoh, K., Aiba, S., & Tagami, H. (1998) · Experimental Dermatology · doi:10.1111/j.1600-0625.1998.tb00332.x · Cited by 89
“Recently we have demonstrated that IFN-g is capable of enhancing the IL-1ra production by differentiated human keratinocytes cultured on a feeder layer (submitted for publication).”
BackgroundInfluentialInterferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine
Tilg, H., & Peschel, C. (1996) · Leukemia & Lymphoma · doi:10.3109/10428199609054802 · Cited by 34
Self-citationUpregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine
Lombardo, S., Mazzon, E., Basile, M., Cavalli, E., Bramanti, P., Nania, R., Fagone, P., Nicoletti, F., & Petralia, M. (2019) · Brain Sciences · doi:10.3390/brainsci9070172 · Cited by 33
“They are produced by M1 macrophages, Th1 and Th17 cells, and include—among others—IL-1, TNF-alpha, IFN-gamma, IL-12, IL-18, IL-22, IL-23, and IL-17.”
Background
Metadata
- Authors
- Tilg, H., Mier, J. W., Vogel, W., Aulitzky, W. E., Wiedermann, C. J., Vannier, E., Huber, C., & Dinarello, C. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-05
- Volume
- 150
- Issue
- 10
- Pages
- 4687-4692
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2114465053
- Cited by
- 136
- References
- 0
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.